BC
TVTX icon

Broadfin Capital’s Travere Therapeutics TVTX Stock Holding History

Broadfin Capital’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q3 		– Sell
-500,000
Closed -$10M – 51
2019
Q2 		$10M Buy
+500,000
New +$9.87M 2.19% 16

Other funds holding TVTX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Macquarie Group
Macquarie Group Sydney, NSW 2000, Australia $16.8B AUM 27.39% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Manulife (Manufacturers Life Insurance)
Manulife (Manufacturers Life Insurance) Canada, Ontario, Canada $116B AUM 26.37% 1-Year Est. Return
CCM
Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return
SCM
Scopia Capital Management New York $146M AUM 25.93% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Broadfin Capital's TVTX Position: Q4 2019 in Review

Broadfin Capital sold out of Travere Therapeutics (TVTX) in Q4 2019, closing a stake of 610,414 shares — an estimated $7.08M sold.

Broadfin Capital first reported a position in TVTX in Q1 2014 and held it in 23 quarters. The position peaked at $77.6M in Q3 2016. 131 funds tracked by Wall St. Rank hold TVTX as of Q4 2019.

  • Broadfin Capital reported no remaining Travere Therapeutics position as of Q4 2019 after selling out during the quarter.
  • Broadfin Capital sold 610,414 Travere Therapeutics shares in Q4 2019, an estimated $7.08M.
  • Broadfin Capital first reported a position in Travere Therapeutics in Q1 2014 and held it in 23 quarters.
  • Broadfin Capital's Travere Therapeutics position peaked at $77.6M in Q3 2016.
  • 131 funds tracked by Wall St. Rank held Travere Therapeutics as of Q4 2019.

Based on Broadfin Capital's 13F filing for Q4 2019, filed 14 Feb 2020.